Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results
Merck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported better-than-expected quarterly results, and raised and narrowed its guidance on strong sales of its b...
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street ...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
Merck's first-quarter results beat expectations amid healthy vaccine-sales growth
Merck & Co. Inc. on Thursday reported first-quarter results that beat analysts' expectations amid strong sales of vaccines and cancer drug Keytruda.
Higher Keytruda Sales To Drive Merck's Q1?
Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates.
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu...
Cramer's week ahead: Earnings from Tesla, Merck and Big Tech
CNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.
Merck (MRK) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.
1 New Green Flag for Moderna and Merck Stock
Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Merck (MRK) stood at $126.15, denoting a -0.47% change from the preceding trading day.
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
Related Companies